Brazil is now demanding that Merck lower the price for its HIV drug Efavirenz to what it is being sold in Thailand. (From $1.59 to 65 cents) If Merck does not agree (which it will) then Brazil's health minister will seek a compulsory license for the drug.
Again, unless companies come up with a long term strategy to deal with pricing in emerging or middle markets, NGOs will continue to use the CL route to ratchet down the price of ALL medicines.
No way to run a business.
Again, unless companies come up with a long term strategy to deal with pricing in emerging or middle markets, NGOs will continue to use the CL route to ratchet down the price of ALL medicines.
No way to run a business.
